- $31.57m
- $184.66m
- $2.69m
Brief: Calyxt Announces Effective Date Of Reverse Stock Split
U.S. RESEARCH ROUNDUP-DR Horton, KB Home, Vir Biotechnology
Calyxt Inc reports results for the quarter ended in December - Earnings Summary
Brief: Calyxt Reports Q4 2022 Financial Results And Provides Corporate Update
Calyxt Inc expected to post a loss of 11 cents a share - Earnings Preview
Brief: Calyxt Inc Announces Its Filing Of Registration Statement On Form S-4 In Connection With Merger With Cibus Global Llc
U.S. STOCKS ON THE MOVE-Chord Energy, Kroger, PetMed Express
Calyxt soars on merger deal with gene-editing co Cibus
U.S. STOCKS ON THE MOVE-DoorDash, Walt Disney, Tesla
U.S. STOCKS ON THE MOVE-Papa John's, Whirlpool, Coca-Cola
Calyxt surges on merger with gene-editing co Cibus
Advisory: Alerts wrongly tagged to Cibus Nordic Real Estate withdrawn
Advisory: Alerts wrongly tagged to Cibus Nordic Real Estate withdrawn
Brief: Calyxt Granted 180-Day Extension By Nasdaq To Regain Compliance With Bid Price Rule
Calyxt Inc reports results for the quarter ended in September - Earnings Summary
Calyxt Inc expected to post a loss of 14 cents a share - Earnings Preview
Brief: Calyxt Successfully Produces Plant-Based Squalene, An Important Ingredient In Personal Care Products And Critical Vaccine Adjuvants
Brief: Calyxt Announces Agreement With Evologic Technologies To Scale Production Of Its Plant-Based Ingredients
Brief: Calyxt Says May Offer And Sell Up To 15.6 Mln Shares Of Common Stock From Time To Time